Meredith Cook Sells 400 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares of the company's stock, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Thursday, February 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $59.54, for a total value of $23,816.00.
• On Monday, January 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $53.92, for a total transaction of $21,568.00.

ANI Pharmaceuticals Stock Performance

ANIP stock traded down $0.13 during midday trading on Tuesday, reaching $64.22. The company had a trading volume of 233,027 shares, compared to its average volume of 238,092. The firm has a market capitalization of $1.40 billion, a PE ratio of -116.76 and a beta of 0.63. The stock has a 50 day moving average price of $58.59 and a 200 day moving average price of $58.07. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

Remove Ads

Analyst Upgrades and Downgrades

ANIP has been the subject of a number of analyst reports. Guggenheim increased their price target on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Leerink Partnrs raised shares of ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research note on Friday. They issued a "buy" rating and a $80.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday. Finally, StockNews.com raised shares of ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Friday. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $79.75.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in ANI Pharmaceuticals by 41.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,899 shares of the specialty pharmaceutical company's stock worth $2,648,000 after buying an additional 13,948 shares during the period. Stonepine Capital Management LLC bought a new position in shares of ANI Pharmaceuticals during the fourth quarter worth about $1,128,000. Rafferty Asset Management LLC bought a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $200,000. ProShare Advisors LLC boosted its stake in ANI Pharmaceuticals by 29.0% during the 4th quarter. ProShare Advisors LLC now owns 6,532 shares of the specialty pharmaceutical company's stock valued at $361,000 after purchasing an additional 1,469 shares during the period. Finally, Nomura Holdings Inc. grew its position in ANI Pharmaceuticals by 1.5% in the 4th quarter. Nomura Holdings Inc. now owns 213,879 shares of the specialty pharmaceutical company's stock worth $11,823,000 after purchasing an additional 3,255 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.